

DAFTAR PUSTAKA

- AdvanDx, Inc. 2008. mupA Evigene®: mupirocin-resistance culture identification kit. <http://www.advandx.com/uploads/documents/pikt107c.pdf>.
- Ammerlaan HS, Kluytmans JA, Wertheim HF, Nouwen JL, Bonten MJ. 2009. Eradication of methicillin-resistant *Staphylococcus aureus* carriage: a systematic review. *Clin Infect Dis*;48:922–30.
- Anthony, R. M., A. M. Connor, E. G. Power, and G. L. French. 1999. Use of the polymerase chain reaction for rapid detection of high-level mupirocin resistance in staphylococci. *Eur. J. Clin. Microbiol. Infect. Dis.* 18:30–34.
- Antonov NK, Garzon MC, Morel KD, Whittier S, Planet PJ, Lauren CT. 2015. High prevalence of mupirocin resistance in *Staphylococcus aureus* isolates from a pediatric population, *Antimicrob. Agents Chemother.* 59 (6) 3350-3356.
- Barakat GI., Nabil YM., 2015. Correlation of mupirocin resistance with biofilm production in methicillin-resistant *Staphylococcus aureus* from surgical site infections in a tertiary centre, Egypt, *Journal of Global Antimicrobial Resistance*, vol 4, hal 16-20
- Bathoorn E., Hetem DJ., Alphenaar J., Kusters JG., and Bonten MJM., 2012. Emergence of High-Level Mupirocin Resistance in Coagulase-Negative Staphylococci Associated with Increased Short-Term Mupirocin Use, *Journal of Clinical Microbiology*, vol 50, no 9, hal 2947–2950

- Bemis DA, Jones RD, Frank LA, Kania SA. 2009. Evaluation of susceptibility test breakpoints used to predict *mecA*-mediated resistance in *Staphylococcus pseudintermedius* isolated from dogs. *J Vet Diagn Invest* 21:53-58. <https://doi.org/10.1177/104063870902100108>.
- Black CC, Solyman SM, Eberlein LC, Bemis DA, Woron AM, Kania SA. 2009. Identification of a predominant multilocus sequence type, pulsed-field gel electrophoresis cluster, and novel staphylococcal chromosomal cassette in clinical isolates of *mecA*-containing, methicillin-resistant *Staphylococcus pseudintermedius*. *Vet Microbiol* 139:333-338. <https://doi.org/10.1016/j.vetmic.2009.06.029>.
- Buffie CG, Pamer EG. 2013. Microbiota-mediated colonization resistance against intestinal pathogens. *Nat Rev Immunol* 13:790-801. <http://dx.doi.org/10.1038/nri3535>.
- Bynoe ET, Elder RH, Comtois RD. 1956. Phage-typing and antibiotic resistance of staphylococci isolated in a general hospital. *Can J Microbiol* 2:346-358. <https://doi.org/10.1139/m56-041>.
- Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. <http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf>. Accessed 7 May 2015.
- Clewell D.B, Francia M.V. 2004. Conjugation in gram-positive bacteria, *Plasmid Boil. Am. Soc. Microbiol.* 227-256.

- Clinical and Laboratory Standards Institute. 2018. Performance standards for antimicrobial susceptibility testing; 19th informational supplement. M100-S20. Clinical and Laboratory Standards Institute, Wayne, PA. 28th Ed.
- Cookson BD. 1998. The emergence of mupirocin resistance: a challenge to infection control and antibiotic prescribing practice, *J. Antimicrob. Chemother.* 41 (1) 11-18.
- Cowan ST, Shaw C, Williams RE. 1954. Type strain for *Staphylococcus aureus* Rosenbach. *J Gen Microbiol* 10:174 -176.
<https://doi.org/10.1099/00221287-10-1-174>.
- David MZ., Daum RS. 2010. Community-associated methicillin-resistant *Staphylococcus aureus* : epidemiology and clinical consequences of an emerging epidemic. *Clinical Microbiology Review*, Vol 23, No.3, hal 616-687
- Deeny SR, Worby CJ, Tosas August O, Cooper BS, Edgeworth J, Cookson B et al., 2015. Impact of mupirocin resistance on the transmission and control of healthcare- associated MRSA, *J. Antimicrob. Chemother.* 70 (12) 3366-3378.
- DeLeo FR, Otto M, Kreiswirth BN, Chambers HF. 2010. Community-associated methicillin- resistant *Staphylococcus aureus*, *Lancet* 375 (9725) 1557-1568.

- Depardieu F, Podglajen I, Leclercq R, Collatz E, Courvalin P. 2007. Modes and modulations of antibiotic resistance gene expression, *Clin. Microbiol. Rev.* 20 (1) 79-114.
- Desroches M, Potier J, Laurent F, Bourrel A.S, Doucet-Populaire F, Decousser J.W, et al. 2013. Prevalence of mupirocin resistance among invasive coagulase-negative staphylococci and *methicillin-resistant Staphylococcus aureus* (MRSA) in France: emergence of a mupirocin-resistant MRSA clone harbouring *mupA*, *J. Antimicrob. Chemother.* 68 (8) 1714-1717.
- Duerenberg RH., Beisser PS., Visschers MJ. 2010. Molecular typing of *Methicillin-Susceptible Staphylococcus aureus* isolates collected in the Yogyakarta area in Indonesia. *Clinical Microbiology Infections*, Vol 16, hal 92-94.
- Dutta P, Das S. 2016. Mammalian antimicrobial peptides: promising therapeutic targets against infection and chronic inflammation, *Curr. Top. Med. Chem.* 16 (1) 99-129.
- Eed EM, Khalifa AS, Taha AA. 2018. The Impact of Methicillin-Resistant *Staphylococcus aureus* (MRSA) Decolonization Protocols on its Mupirocin and Chlorhexidine Susceptibility. *American Journal of Clinical Microbiology and Antimicrobials*, hal 2.
- EUCAST. 2000. Determination of minimum inhibitory concentrations (MICs) of antibacterial agents by agar dilution. European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), hal 4.

- Fleming A. 2001. On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of *B. influenzae*. 1929. Bull World Health Organ 79:780 -790.
- Fooladi AA, Ashrafi E, Tazandareh SG, Koosha RZ, Rad HS, Amin M, *et al.* 2015. The distribution of pathogenic and toxigenic genes among MRSA and MSSA clinical isolates. Microb Pathog.;81:60-66.
- Fujimura S, Watanabe A. 2003. Survey of high-and low-level mupirocin-resistant strains of methicillin-resistant *Staphylococcus aureus* in 15 Japanese hospitals, Chemotherapy. 49 (1-2) 36-38.
- Gallego IM., Infiesta L., Viedma E., Montarelo DP., Chaves F. 2015. Chlorhexidine and mupirocin susceptibilities in methicillin-resistant *Staphylococcus aureus* isolates from bacteraemia and nasal colonisation, Journal of Global Antimicrobial Resistance, hal 1-5
- Gao SS, Hothersall J, Wu Je, Murphy AC, Song Z, Stephens ER, *et al.* 2014. Biosynthesis of Mupirocin by *Pseudomonas fluorescens* NCIMB 10586 Involves Parallel Pathways, J. Am. Chem. Soc. 136 (14) 5501-5507.
- Gillespie WA, Alder VG. 1957. Control of an outbreak of staphylococcal infection in a hospital. Lancet 272:632- 634. [https://doi.org/10.1016/S0140-6736\(57\)91091-7](https://doi.org/10.1016/S0140-6736(57)91091-7).
- Gould D, Chamberlaine A. 1995. *Staphylococcus aureus*: a review of the literature. J Clin Nurs 4:5-12. <https://doi.org/10.1111/j.1365-2702.1995.tb00004.x>.

Grema HA. 2015. *Methicillin resistant Staphylococcus aureus (MRSA):a review*.
Adv Anim Vet Sci 3:79 -98.
<https://doi.org/10.14737/journal.aavs/2015/3.2.79.98>.

Harbarth S, Dharan S, Liassine N, Herrault P, Auckenthaler R, Pittet D. 1999.
Randomized, placebo-controlled, double-blind trial to evaluate the
efficacy of mupirocin for eradicating carriage of methicillin-resistant
Staphylococcus aureus, *Antimicrob. Agents Chemother.* 43 (6) 1412-
1416.

Hassall JE, Rountree PM. 1959. Staphylococcal septicaemia. *Lancet* i:213-217.

Hayden MK., Lolans K., Haffenreffer K., 2016. Chlorhexidine and Mupirocin
Susceptibility of Methicillin-Resistant *Staphylococcus aureus* Isolates in
the REDUCE-MRSA Trial, *Journal of Clinical Microbiology*, vol 54, no
11, hal 2735-2740

Hogue JS, Buttke P, Braun LE, Fairchok MP. 2010. Mupirocin resistance related to
increasing mupirocin use in clinical isolates of methicillin-resistant
Staphylococcus aureus in a pediatric population, *J. Clin. Microbiol.* 48 (7)
2599-2600.

Hong W, Zeng J, Xie J. 2014. Antibiotic drugs targeting bacterial RNAs, *Acta
Pharm. Sin. B* 4 (4) 258-265.

Hosseini HM., Kiyani N., Amin M., Hedayati M., Fooladi AAI., 2016. Distribution
of high-level mupirocin resistance among clinical MRSA, *Antimicrobial
Original Research Paper*, hal 1-6

- Hughes J, Stabler R, Gaunt M, Karadag T, Desai N, Betley J, et al. 2015. Clonal variation in high-and low-level phenotypic and genotypic mupirocin resistance of MRSA isolates in south-east London, J. Antimicrob. Chemother. 70 (12) 3191-3199.
- Hurdle J.G, O’neill AJ, Ingham E, Fishwick C, Chopra I. 2004. Analysis of mupirocin resistance and fitness in *Staphylococcus aureus* by molecular genetic and structural modeling techniques, Antimicrob. Agents Chemother. 48 (11) 4366-4376.
- Hurdle, J. G., O’Neill AJ, Mody L, Chopra I, and Bradley SF. 2005. *In vivo* transfer of high-level mupirocin resistance from *Staphylococcus epidermidis* to methicillin resistant *Staphylococcus aureus* associated with failure of mupirocin prophylaxis. J. Antimicrob. Chemother. **56**:1166–1168.
- Jessen O, Rosendal K, Bulow P, Faber V, Eriksen KR. 1969. Changing staphylococci and staphylococcal infections. A ten-year study of bacteria and cases of bacteremia. N Engl J Med 281:627- 635.
- Jevons MP. 1961. “Celbenin” -resistant staphylococci. Br Med J1:124 -125.
- J.I. Yoo, E.S. Shin, J.O. Cha, J.K. Lee, Y.H. Jung, K.M. Lee, et al., 2009. Clonal Dissemination and mupA Gene Polymorphism of Mupirocin-Resistant *Staphylococcus aureus* Isolates from Long-Term-Care Facilities in South Korea, Antimicrob. Agents Chemother. 53 (12) 5319.

- Kirby WM. 1944. Extraction of a highly potent penicillin inactivator from penicillin resistant staphylococci. *Science* 99:452-453.
<https://doi.org/10.1126/science.99.2579.452>.
- Klein E, Smith DL, Laxminarayan R. 2007. Hospitalizations and deaths caused by methicillin-resistant *Staphylococcus aureus*, United States, 1999-2005. *Emerg Infect Dis.*;13(12):1840-6.
- Lakhundi S, Zhang K. 2018. Methicillin-Resistant *Staphylococcus aureus*: Molecular Characterization, Evolution, and Epidemiology. *Clinical Microbiology Review*, Vol 31, hal 3-8.
- Landau R. 1999. *Pharmaceutical Innovation: Revolutionizing Human Health*. Philadelphia: Chemical Heritage Press.
- Leber AL. 2016. *Clinical Microbiology Procedures Handbook*. ASM Press. 4th Edition. Hal 837
- Lebreton F, van Schaik W, McGuire AM, Godfrey P, Griggs A, Mazumdar V, Corander J, Cheng L, Saif S, Young S, Zeng Q, Wortman J, Birren B, Willems RJ, Earl AM, Gilmore MS. 2013. Emergence of epidemic multidrug-resistant *Enterococcus faecium* from animal and commensal strains. *mBio* 4:e00534-13. <http://dx.doi.org/10.1128/mBio.00534-13>.
- Lederberg J. 1957. Mechanism of action of penicillin. *J Bacteriol*, Vol 73, hal 144
- Lee A, Macedo-Vinas M, Francois P, Renzi G, Vernaz N, Schrenzel J, et al., 2011. Trends in mupirocin resistance in methicillin-resistant *Staphylococcus*

aureus and mupirocin consumption at a tertiary care hospital, *J. Hosp. Infect.* 77 (4) 360-362.

Lee H, Lim H, Bae IK, Yong D, Jeong SH, Lee K, et al. 2013. Coexistence of mupirocin and antiseptic resistance in methicillin-resistant *Staphylococcus aureus* iso-lates from Korea. *Diagn Microbiol Infect Dis*;75:308–12.

Liberati A, D'Amico R, Pifferi S, Torri V, Brazzi L, Parmelli E. 2009. Antibiotic prophylaxis to reduce respiratory tract infections and mortality in adults receiving intensive care. *Cochrane Database Syst Rev* 2009:CD000022. <http://dx.doi.org/10.1002/14651858.CD000022.pub3>.

Loeffler A, Linek M, Moodley A, Guardabassi L, Sung JM, Winkler M, Weiss R, Lloyd DH. 2007. First report of multiresistant, *mecA*-positive *Staphylococcus intermedius* in Europe: 12 cases from a veterinary dermatology referral clinic in Germany. *Vet Dermatol* 18:412- 421. <https://doi.org/10.1111/j.1365-3164.2007.00635.x>.

Lowy FD. 2003. Antimicrobial resistance: the example of *Staphylococcus aureus*. *J Clin Invest* 111:1265-1273. <https://doi.org/10.1172/JCI18535>.

Magill SS, Edwards JR, Bamberg W, Beldavs ZG, Dumyati G, Kainer MA, Lynfield R, Maloney M, McAllister-Hollod L, Nadle J, Ray SM, Thompson DL, Wilson LE, Fridkin SK. 2014. Multistate pointprevalence survey of health care-associated infections. *N Engl J Med* 370:1198–1208. <http://dx.doi.org/10.1056/NEJMoa1306801>.

- Malaviolle, X., C. Nonhoff, O. Denis, S. Rottiers, and M. J. Struelens. 2008. Evaluation of disc diffusion methods and Vitek 2 automated system for testing susceptibility to mupirocin in *Staphylococcus aureus*. *J. Antimicrob. Chemother.* 62:1018–1023.
- Mayer S, Boos M, Beyer A, Fluit AC, Schmitz FJ. 2001. Distribution of the antiseptic resistance genes *qacA*, *qacB* and *qacC* in 497 methicillin-resistant and -susceptible European isolates of *Staphylococcus aureus*. *J Antimicrob Chemother*;47:896–7.
- Moorhouse E, Fenelon L, Hone R, Smyth E, McGahon J, Dillon M, 1996. *Staphylococcus aureus* sensitivity to various antibiotics—a national survey in Ireland 1993. *Ir. J. Med. Sci.* 165 (1) 41–43.
- Nakama T, Nureki O, Yokoyama S. 2001. Structural basis for the recognition of isoleucyl-adenylate and an antibiotic, mupirocin, by isoleucyl-tRNA synthetase. *J Biol Chem*; 276:47387–93.
- Noguchi N, Hase M, Kitta M, Sasatsu M, Deguchi K, Kono M. 1999. Antiseptic susceptibility and distribution of antiseptic-resistance genes in methicillin-resistant *Staphylococcus aureus*. *FEMS Microbiol Lett* ;172:247–53.
- Noguchi N, Suwa J, Narui K, Sasatsu M, Ito T, Hiramatsu K, et al. 2005. Susceptibilities to antiseptic agents and distribution of antiseptic-resistance genes *qacA/B* and *smr* of methicillin-resistant *Staphylococcus aureus* isolated in Asia during 1998 and 1999. *J Med Microbiol* ;54:557–65.

- Neushul P. 1993. Science, government, and the mass production of penicillin. *J Hist Med Allied Sci* 48:371-395. <https://doi.org/10.1093/jhmas/48.4.371>.
- Ogston A. 1881. Report upon micro-organisms in surgical diseases. *Br Med J* 1:369-375.
- Oostdijk EA, de Smet AM, Blok HE, Thieme Groen ES, van Asselt GJ, Benus RF, Bernards SA, Frenay IH, Jansz AR, de Jongh BM, Kaan JA, Leverstein-van Hall MA, Mascini EM, Pauw W, Sturm PD, Thijsen SF, Kluytmans JA, Bonten MJ. 2010. Ecological effects of selective decontamination on resistant gram-negative bacterial colonization. *Am J Respir Crit Care Med* 181:452-457. <http://dx.doi.org/10.1164/rccm.200908-1210OC>.
- Pappa KA. 1990. The clinical development of mupirocin, *J. Am. Acad. Dermatol.* 22 (5) 873-879.
- Patel JB, Gorwitz RJ, Jernigan JA, 2009. Mupirocin resistance, *Clin. Infect. Dis.* 49 (6) 935-941.
- Peraturan Menteri Kesehatan Republik Indonesia Nomor 8 Tahun 2015 Tentang Program Pengendalian Resistensi Antimikroba Di Rumah Sakit.
- Perez-Roth E, Lopez-Aguilar C, Alcoba-Florez J, Mendez-Alvarez S, 2006. High-level mupirocin resistance within methicillin-resistant *Staphylococcus aureus* pandemic lineages, *Antimicrob. Agents Chemother.* 50 (9) 3207-3211.

- Perkins D, Hogue JS, Fairchok M, Braun L, Viscount HB, 2008. Mupirocin resistance screening of methicillin-resistant *Staphylococcus aureus* isolates at Madigan Army Medical Center, Mil. Med. 173 (6) 604-608.
- Pierce R, Bryant K, Elward A, Lessler J, Milstone AM, 2016. Gram-negative and fungal infections following mupirocin-based methicillin-resistant *Staphylococcus aureus* decolonization in neonates, Open Forum Infectious Diseases, Oxford University Press.
- Poovelikunnel T, Gethin G, Humphreys H, 2015. Mupirocin resistance: clinical implications and potential alternatives for the eradication of MRSA, J. Antimicrob. Chemother. 70 (10) 2681-2692.
- Q.-Z. Liu, Q. Wu, Y.-B. Zhang, M.-N. Liu, F.-P. Hu, X.-G. Xu, et al., 2010. Prevalence of clinical methicillin-resistant *Staphylococcus aureus* (MRSA) with high-level mupirocin resistance in Shanghai and Wenzhou, China, Int. J. Antimicrob. Agents 35 (2) 114-118.
- Rahman M, Noble W, Cookson B, Baird D, Coia J, 1987. Mupirocin-resistant *Staphylococcus aureus*, Lancet 330 (8555) 387-388.
- Rammelkamp CH, Maxon T. 1942. Resistance of *Staphylococcus aureus* to the action of penicillin. Proc Soc Exp Biol Med 51:386 -389.
<https://doi.org/10.3181/00379727-51-13986>.
- Ramsey M.A, Bradley S.F, Kauffman C.A, Morton T.M, Patterson J.E, Reagan D.R, 1998. Characterization of mupirocin-resistant *Staphylococcus aureus*

from different geographic areas, *Antimicrob. Agents Chemother.* 42 (5) 1305.

Rodvold KA, McConeghy KW. 2014. Methicillin-resistant *Staphylococcus aureus* therapy: past, present, and future. *Clin Infect Dis*;58(Suppl. 1):S20–7.

Rudresh MS, Ravi GS, Motagi A, Alex AM, Sandhya P, Navaneeth BV, 2015. Prevalence of mupirocin resistance among staphylococci, its clinical significance and relationship to clinical use, *J. Lab. Phys.* 7 (2) 103.

Schmitz F.J, Lindenlauf E, Hofmann B, Fluit AdC, Verhoef J, Heinz H et al., 1998. The prevalence of low-and high-level mupirocin resistance in staphylococci from 19 European hospitals, *J. Antimicrob. Chemother.* 42 (4) 489-495.

Seah C, Alexander DC, Louie L, Simor A, Low DE, Longtin J, et al., 2012. MupB, a new high-level mupirocin resistance mechanism in *Staphylococcus aureus*, *Antimicrob. Agents Chemother.* 56 (4) 1916-1920.

Shanson DC. 1981. Antibiotic-resistant *Staphylococcus aureus*. *J Hosp Infect.*;2:11–36.

Simone M-Finstrom, Spivak M. 2010. Propolis and bee health: the natural history and significance of resin use by honey bees, *Apidologie.* 41 (3) 295-311.

Simor AE, Stuart TL, Louie L, Watt C, Ofner-Agostini M, Gravel D, et al. 2007. Mupirocin-resistant, methicillin-resistant *Staphylococcus aureus* strains in Canadian hospitals, *Antimicrob. Agents Chemother.* 51 (11) 3880-3886.

- Sivaraman K, Venkataraman N, Cole AM. 2009. Staphylococcus aureus nasal carriage and its contributing factors. *Future Microbiol*; 4:999–1008.
- Sutherland R, Comber K, Mizen L, Slocombe B, Clayton J, 1976. Pseudomonic acid, an antibiotic produced by pseudomonas fluorescens, Proceedings of the 16th Interscience Conference on Antimicrobial Agents and Chemotherapy.
- Sutherland R, Boon R, Griffin K, Masters P, Slocombe B, White A. 1985. Antibacterial activity of mupirocin (pseudomonic acid), a new antibiotic for topical use, *Antimicrob. Agents Chemother.* 27 (4) 495-498.
- Thomas CM, Hothersall J, Willis CL, Simpson TJ. 2010. Resistance to and synthesis of the antibiotic mupirocin, *Nat. Rev. Microbiol.* 8 (4) 281.
- Upton A, Lang S, Heffernan H. 2003. Mupirocin and Staphylococcus aureus: a recent paradigm of emerging antibiotic resistance, *J. Antimicrob. Chemother.* 51 (3) 613-617.
- Tsubakishita S, Kuwahara-Arai K, Sasaki T, Hiramatsu K. 2010. Origin and molecular evolution of the determinant of methicillin resistance in staphylococci. *Antimicrob Agents Chemother* 54:4352- 4359.
<https://doi.org/10.1128/AAC.00356-10>.
- Van Rijen MM, Bonten M, Wenzel RP, Kluytmans JA. 2008. Intranasal mupirocin for reduction of Staphylococcus aureus infections in surgical patients with nasal carriage: a systematic review. *J Antimicrob Chemother* ;61:254–61.

- Walsh SE, Maillard JY, Russell AD, Catrenich CE, Charbonneau DL, Bartolo RG. 2003. Development of bacterial resistance to several biocides and effects on antibiotic susceptibility. *J Hosp Infect* ;55:98-107.
- Wertheim HF, Melles DC, Vos MC, van Leeuwen W, van Belkum A, Verbrugh HA, Nouwen JL. 2005. The role of nasal carriage in *Staphylococcus aureus* infections. *Lancet Infect Dis* 5:751–762. [http://dx.doi.org/10.1016/S1473-3099\(05\)70295-4](http://dx.doi.org/10.1016/S1473-3099(05)70295-4).
- Williams RE, Jevons MP, Shooter RA, Hunter CJ, Girling JA, Griffiths JD, Taylor GW. 1959. Nasal staphylococci and sepsis in hospital patients. *Br Med J* 2:658-662. <https://doi.org/10.1136/bmj.2.5153.658>.
- Yun HJ, Lee SW, Yon GM, Kim SY, Choi SY, Lee YS, Choi EC, Kim S, 2003. Prevalence and mechanisms of low- and high-level mupirocin resistance in staphylococci isolated from a Korean hospital. *Journal of Antimicrobial Chemotherapy*. Hal 3-5.
- Zeng D, Zhao J, Chung HS, Guan Z, Raetz CR, Zhou P, 2013. Mutants resistant to LpxC inhibitors by rebalancing cellular homeostasis, *J. Biol. Chem.* 288 (8) 5475-5486.
- Zhu W, Clark N, Patel J.B. 2012. pSK41-like plasmid is necessary for Inc18-like vanA plasmid transfer from *Enterococcus faecalis* to *Staphylococcus aureus* in vitro, *Antimicrob. Agents Chemother.* AAC. 01587-12.